Tag Archives: pcyc

Pharmacyclics’ Imbruvica Wins Second Cancer Approval

The FDA approved Pharmacyclics’ (PCYC) Imbruvica for chronic lymphocytic leukemia early Wednesday afternoon, abruptly sending the stock up nearly 7% on the stock market today. Pharmacyclis and its partner, Johnson & Johnson (JNJ) unit Janssen Biotech, said the agency had approved the product to treat the deadly blood cancer in patients who’d received at least one prior therapy. It’s the second indication for Imbruvica, which was launched back in

Pharmacyclics, Valeant, Celgene Up On Bullish News

Big-cap drug stocks Pharmacyclics, Valeant Pharmaceuticals and Celgene were all moving up Tuesday as the new year brought news that promised more expansion for all of them. Pharmacyclics (PCYC) vaulted 20% to 125.90 after saying a clinical trial of Imbruvica would be halted because the drug had already met its goals. The trial compared survival rates in patients with refractory chronic lymphocytic leukemia (CLL) or small lymphocytic

Pharmacyclics Drug Trial To End Early On Strong Data

Pharmacyclics (PCYC) announced Tuesday that a late-stage trial of its blood-cancer drug Imbruvica will be stopped early, as it has already proven its effectiveness. Pharmacyclics stock jumped 19% in morning trading in the stock market today. The trial in question was comparing survival rates in patients with refractory chronic lymphocytic leukeumia (CLL) or small lymphocytic lymphoma who were treated with Imbruvica vs. those treated with current